Horizon Therapeutics Receives $7,294,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ea6e458f-e4e3-4604-81c6-a17296122279&Preview=1 - Date
3/31/2010 - Company Name
Horizon Therapeutics - Mailing Address
1033 Skokie Boulevard Northbrook, IL 60062 - Company Description
Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, will enter Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development. - Website
http://www.horizontherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$7,294,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
Essex Woodlands Health Ventures - Venture Investor
Undisclosed
